Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 05:42 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Disease Control and Safety in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Switching From Natalizumab to Fingolimod
NCT01499667 · Novartis Pharmaceuticals · PHASE3 · terminated · last registry update 2014-08-08 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Based on recent publications, determination of natalizumub washout period was no longer relevant.” | – | Registry record, Novartis Pharmaceuticals |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against S1PR5 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2015-06-22Results posted on the registry: Novartis Pharmaceuticals, Fingolimod + Standard MS DMT (NCT01317004)
- 2015-05-06Phase 3 first posted: Celgene, RPC1063 + Placebo (NCT02435992)
- 2015-05-04Results posted on the registry: Novartis Pharmaceuticals, Fingolimod 0.5mg/daily + Placebo (NCT01757691)
- 2015-05-04Also stopped (terminated): Novartis Pharmaceuticals, Fingolimod 0.5mg/daily + Placebo (NCT01757691)
- 2015-03-19Results posted on the registry: Novartis Pharmaceuticals, Fingolimod (NCT01497262)
- 2014-11-19Phase 3 first posted: Celgene, Ozanimod + Interferon beta-1a (NCT02294058)
- 2014-09-30Also stopped (withdrawn): Novartis Pharmaceuticals, a drug against S1PR5 (NCT01709812)
- 2014-09-25Results posted on the registry: Novartis Pharmaceuticals, Venlafaxine + Fluoxetine (NCT01436643)
- 2014-09-25Also stopped (terminated): Novartis Pharmaceuticals, Venlafaxine + Fluoxetine (NCT01436643)
- 2014-08-08Results posted on the registry: Novartis Pharmaceuticals, Fingolimod + Interferon beta - 1a (IFN) (NCT01534182)
- 2014-01-28Phase 3 first posted: Celgene, Ozanimod + Ozanimod placebo (NCT02047734)
- 2013-12-05Results posted on the registry: Novartis Pharmaceuticals, Fingolimod + Standard MS DMTs (NCT01216072)
- 2013-09-12Phase 3 first posted: Novartis Pharmaceuticals, fingolimod + Placebo (6mos) + open label fingolimod (6 mos) (NCT01941004)
- 2013-09-04Results posted on the registry: Novartis, Fingolimod (NCT00670449)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision